The dimethylmethylene blue assay showed higher concentrations of glycosaminoglycans in many synovial fluids from patients with rheumatoid arthritis (RA) than in autologous sera or sera or synovial fluids from normal subjects. These results were taken to suggest that the glycosaminoglycans in RA synovial fluid were abnormally raised and derived from cartilage. To discover what stimulated such glycosaminoglycan release in RA joints relations were sought between synovial fluid concentrations of glycosaminoglycans and immunological and inflammatory mediators. It was shown that RA synovial fluid glycosaminoglycan concentrations correlated with synovial fluid C3d concentrations but not with synovial fluid rheumatoid factor concentrations, polymorphonuclear leucocyte numbers, myeloperoxidase concentrations, or the ability of the synovial fluids to release free radicals from normal polymorphonuclear leucocytes. A correlation was found between synovial fluid C3d and interleukin 1 concentrations as judged by both lymphocyte activating factor activity and immunoassay, but no significant correlation was detected between interleukin 1 and glycosaminoglycan concentrations. It is suggested that in the rheumatoid joint locally produced cytokines, in addition to interleukin 1, together stimulate glycosaminoglycan release from cartilage and render it vulnerable to attack by other processes.
Several hypotheses have been advanced to explain the pathogenesis of inflammation and joint damage in rheumatoid arthritis (RA). For example, it has been suggested that immune complexes in synovial fluid activate complement thereby attracting polymorphonuclear leucocytes into the joint space. Phagocytosis of the complexes triggers the release of polymorphonuclear leucocyte lysosomal enzymes and free radicals into the joint space and these may cause joint damage. This scheme is supported by the finding of IgG aggregates,l activated complement components,2 high numbers of polymorphonuclear leucocytes, polymorphonuclear leucocyte lysosomal enzymes,3 and products of free radical action in RA synovial fluids.4 Polymorphonuclear leucocyte derived enzymes have been detected in arthritic cartilage from experimental animals' and free radicals have been shown to degrade cartilage matrix in vitro. 6 Another hypothesis suggests that local release of cytokines occurs in the joint and these A E Bedwell, R A Cooper, C W Hutton, stimulate chonodrocytes and osteoclasts to break down cartilage and bone respectively. The original impetus for this theory came from the discovery by Fell and Jubb that a factor from synovial membrane promoted-cartilage degradation. 7 More recently, cytokines, such as interleukin 1 and tumour necrosis factor, were shown to stimulate chondrocytes to degrade cartilage matrix8 ' and to stimulate osteoclasts to resorb bone'0 11 in vitro, and these cytokines have been detected in RA synovial fluids. A third hypothesis suggests that sensitised T lymphocytes react with antigen(s) in the joint and liberate lymphokines. Some of these would directly'2 or indirectly (by stimulating other cells to produce cytokines) stimulate chondrocytes and osteoclasts to break down cartilage and bone respectively. Other lymphokines may activate phagocytic cells enabling them to bind collagen and modify the local environment so that their extracellular enzymes can initiate collagen degradation.'3 There is unequivocal experimental evidence from animal models that T cell reactions with antigens on or in the joint initiate arthritis.""1' In addition, T lymphocytes are prominent in rheumatoid synovial membranes, '6 17 and T lymphocytes already activated in vivo have been identified in a number of laboratories, including our own. 8 From the observations summarised above it is apparent that a number of immune and inflammatory reactions are taking place in the joints of patients with RA. It remains to be established which (if any) of these reactions, either alone or in concert, causes joint damage. Our study attempts to approach this problem. Firstly, as degrading cartilage releases glycosaminoglycans in vitro, concentrations of glycosaminoglycan in synovial fluids were measured. Next, the concentrations of a number of putatively destructive immunological and inflammatory mediators were measured and correlations sought between their concentrations and glycosaminoglycan concentrations.
Patients and methods

PATIENTS
All patients (120 women, 56 men) fulfilled revised criteria for the diagnosis of RA. ' the first was used to measure the total leucocyte count and the second was centrifuged within two hours of collection. A portion of the cell pellet was applied to a slide, air dried, and stained with Giemsa for differential leucocyte counts. The cell free supernate was stored in aliquots at -70°C, apart from 2-3 ml which was mixed with ethylenediaminetetra-acetic acid (EDTA) before storage at -70°C. Serum samples were collected and separated from whole venous blood within one hour of arthrocentesis and stored in aliquots at -700C. Samples of synovial fluid were also obtained from 28 patients with osteoarthritis, nine of whom had radiographic or synovial fluid evidence, or both, of crystal deposits. These samples were processed and stored in an identical way to the RA fluids. This estimation was performed as described previously.25 Essentially, polyethylene glycol (2 5%) precipitates of synovial fluids were incubated on the wells of plates which had been coated with monoclonal IgM antihuman C3d. 26 After washing, the amount of IgG attached to the plates was estimated by measuring the uptake of 1251I labelled monoclonal antihuman IgG. Counts obtained from control wells which had been blocked and incubated with antihuman IgG alone were subtracted from each sample count and the results expressed as a percentage of the total radioactivity bound to each well.
RHEUMATOID FACTOR (RF) ASSAYS
These radioimmunoassays were performed as described previously. 27 (14) *pg/ml whole synovial fluid.
after addition of 1,9-dimethylmethylene blue. Figure 1 shows As raised RF concentrations are the most consistent abnormality in RA sera and synovial fluids IgM RF concentrations in RA synovial fluid were measured and relations sought between their level and glycosaminoglycan concentrations. Figure 4 shows that no correlation (n=37, r=0-34, NS) existed between glycosaminoglycan and IgM RF concentrations. Similar results were obtained for IgG RF levels and glycosaminoglycan concentrations (n=37, r=0-24, NS). The possible influence of complement activation and of the complexes which trigger activation was examined. Figure 5 shows the correlation (n=34, r=0-62, p<0-01) between glycosaminoglycan and C3d concentrations, which was confirmed with a second series of RA periments have shown that intra-articular injection of agents, which either inhibit the synthetic free radicals from normal polymorphonuclear capacity of chondrocytes or their production of leucocytes was measured but only 7/47 were degradative enzymes, cause a net loss of cartilage active, and thus this variable too was unrelated and also increased glycosaminoglycan concento glycosaminoglycan concentrations.
trations in synovial fluid, at least in the short Complement activating immunoglobulin term.36 37 In view of these findings and because aggregates but not immunoglobulin aggregates higher concentrations ofglycosaminoglycan were alone32 have been shown to stimulate the release found in many RA synovial fluids than in of interleukin 1-a known stimulant of cartilage autologous serum samples and normal synovial degradation-from monocytes. These findings fluids it seems reasonable to assume that the prompted us to ask, firstly, if there is a relation glycosaminoglycans found in RA synovial fluid between complement activation in RA synovial derive from cartilage. Whether the high concenfluid and synovial fluid interleukin 1 concentra-trations found in RA synovial fluid result from tions, and, secondly, if the relation (reported increased synthesis and release of RA cartilage above) between C3d concentrations and glycos-glycosaminoglycan or from increased degradaaminoglycan concentrations might be due to tion of cartilage matrix glycosaminoglycan complement activation stimulating local inter-remains unclear, though degradation seems the leukin 1 production, which in turn stimulates most likely. A third possibility-namely, that glycosaminoglycan release from cartilage. Figure the process which leads to removal of glycos-6 shows that the levels of synovial fluid lympho-aminoglycan from the joint space is inhibited cyte activating factor activity and C3d were in patients with RA, is not supported by animal related (n=25, r=0 68, p<001). In addition, experiments, which showed that the clearance synovial fluid interleukin l1 concentrations, as rate of glycosaminoglycan from normal and judged by an ELISA, correlated with C3d arthritic synovial fluids was similar (half lives of concentrations (n=9, r=061, p<005). Finally, 12 hours and 14 hours respectively).38 a possible relation between synovial fluid glycosAs already mentioned (see 'Introduction') a aminoglycan concentrations and interleukin 1 number of processes take place in RA joints concentrations was sought. No significant rela-which might affect the cartilage. It was hoped to tion (n=20, r=0-42, NS) between immuno-elucidate which (if any) of these processes is reactive interleukin 1B concentrations and gly-important in relation to cartilage degradation by cosaminoglycan was found and no relation asking if particular initiators or mediators of (n=20, r=0-29, NS) between lymphocyte acti-immunological and inflammatory joint reactions vating factor activity and glycosaminoglycan were related to synovial fluid glycosaminoglycan concentrations.
concentrations 
